Interestingly, we found that ruxolitinib, a specific JAK1/2 inhibitor which used for myelofibrosis treatment, could substantially reduce plasma IL-6, IL-1β, IFN-γ and TNF-α contents in atherosclerotic rabbits. Here, IFNG is linked to myelofibrosis.